Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Maestroni

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
International Journal of Oncology|May 5, 2011
Hematopoietic rescue in mice via alpha 1-adrenoceptors on bone marrow B cell precursorsM Togni, G Maestroni
Cancer|February 1, 1994
A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasmsP Lissoni, S Barni, A Ardizzoia, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 1, 1997
Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatoninP Lissoni, G Tancini, S Barni, et al.
Oncology|January 1, 1996
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy aloneP Lissoni, S Meregalli, L Nosetto, et al.
British Journal of Cancer|June 11, 1999
Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancerM Ghielmini, O Pagani, J de Jong, et al.
Neuro Endocrinology Letters|May 4, 2001
A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophreniaD Viganò, P Lissoni, F Rovelli, et al.
Oncology Reports|May 21, 2011
Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasmsP Lissoni, A Ardizzoia, S Barni, et al.
Tumori|December 31, 1992
Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinomaS Barni, P Lissoni, M Cazzaniga, et al.
Oncology Reports|May 21, 2011
Preoperative neuroimmunotherapy with subcutaneons low-dose interleukin-2 and melatonin in patients with gastrointestinal tumors - its efficacy in preventing surgery-induced lymphocytopeniaF Brivio, P Lissoni, L Fumagalli, et al.
European Urology|January 1, 1997
Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue aloneP Lissoni, M Cazzaniga, G Tancini, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
International Journal of Oncology|May 5, 2011
Hematopoietic rescue in mice via alpha 1-adrenoceptors on bone marrow B cell precursorsM Togni, G Maestroni
Cancer|February 1, 1994
A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasmsP Lissoni, S Barni, A Ardizzoia, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 1, 1997
Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatoninP Lissoni, G Tancini, S Barni, et al.
Oncology|January 1, 1996
Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy aloneP Lissoni, S Meregalli, L Nosetto, et al.
British Journal of Cancer|June 11, 1999
Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancerM Ghielmini, O Pagani, J de Jong, et al.
Neuro Endocrinology Letters|May 4, 2001
A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophreniaD Viganò, P Lissoni, F Rovelli, et al.
Oncology Reports|May 21, 2011
Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasmsP Lissoni, A Ardizzoia, S Barni, et al.
Tumori|December 31, 1992
Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinomaS Barni, P Lissoni, M Cazzaniga, et al.
Oncology Reports|May 21, 2011
Preoperative neuroimmunotherapy with subcutaneons low-dose interleukin-2 and melatonin in patients with gastrointestinal tumors - its efficacy in preventing surgery-induced lymphocytopeniaF Brivio, P Lissoni, L Fumagalli, et al.
European Urology|January 1, 1997
Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue aloneP Lissoni, M Cazzaniga, G Tancini, et al.
Pageof 1